Presumed Pyogenic Granuloma Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy
Jesse J Jung 1, 2, Kara E Della Torre 1, 2, 3, Millie R Fell 1, Christopher C Teng 1, 4, K Bailey Freund*, 1, 2, 3, 5
Identifiers and Pagination:Year: 2011
First Page: 59
Last Page: 62
Publisher ID: TOOPHTJ-5-59
Article History:Received Date: 12/5/2011
Revision Received Date: 30/7/2011
Acceptance Date: 16/9/2011
Electronic publication date: 19/12/2011
Collection year: 2011
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
To report a case of a presumed pyogenic granuloma at the site of multiple intravitreal anti-Vascular Endothelial Growth Factor (VEGF) injections. Intravitreal anti-VEGF injections can be complicated by a localized reaction of the conjunctiva.
Age-related macular degeneration (AMD) is one of the most common causes of severe, irreversible vision loss in older adults in developed countries. Neovascular AMD is characterized by abnormal growth of new blood vessels under or within the macula . Vascular endothelial growth factor A (VEGF) is a key modulator of angiogenesis and promotes neovascularization in AMD [1-4]. Currently, several anti-VEGF drugs such as pegaptanib, ranibizumab and bevacizumab are used via the intravitreal route for treatment of neovascular AMD .
Ranibizumab (Lucentis, Genentech, San Francisco, USA) is a recombinant humanized monoclonal G1K isotype antibody Fab with anti-angiogenetic VEGF A blocking properties [1-4]. The Food and Drug Administration (FDA) approved Ranibizumab since 2006 as an intravitreal injection treatment for neovascular AMD [1,5]. Bevacizumab (Avastin, Genentech, San Francisco, USA) is a recombinant humanized full-length antibody that binds to all isoforms of VEGF. It was initially approved by the FDA for intravenous use against metastatic colorectal cancer, but is now commonly used off-label to treat a variety of retinal disorders including neovascular AMD, diabetic macular edema, and retinal vein occlusion .
Several adverse reactions after intravitreal injections of anti-VEGF treatment have been reported including subconjunctival hemorrhage [4-7], conjunctival hyperemia [4-7], transient and/or sustained elevated intraocular pressure (IOP) [1,4-9], anterior uveitis [1,8-10], iatrogenic cataract [1,5], vitreous hemorrhage [1,4], retinal tear or detachment [1,4], central retinal vein occlusion  and endophthalmitis [1,4]. We report a case of a localized, subconjunctival, nodular inflammatory reaction at the site of multiple ranibizumab injections. Based on clinical appearance, anterior segment imaging and improvement with topical steroid treatment, we believe this lesion to be a pyogenic granuloma. To the best of our knowledge, this is the first case of pyogenic granuloma observed following intravitreal injections of anti-VEGF therapy.
An 87-year-old Caucasian man treated for neovascular AMD presented complaining of eye pain and redness one week after his last intravitreal ranibizumab injection in the right eye (Fig. 1a). The patient received OCT guided treatment with bevacizumab (0.125mg/0.05ml) starting in October 2005 prior to Federal Drug Administration (FDA) approval of ranibizumab for AMD treatment and received three bevacizumab (0.125mg/0.05ml) over an 8 month period of time. He elected to transition to a treat and extend protocol after FDA approval of ranibizumab for treatment of neovascular AMD and received twenty-one ranibizumab (0.5mg/0.05ml) injections without complications starting August 2006 and continued over a 48 month period time with his last injection on August 2010. All injections were administered 3.5-4mm posterior to the limbus in the inferotemporal quadrant varying one or two clock hours from previous injection sites using a 32 gauge needle following three drops of topical proparacaine (0.5%), two drops of ofloxacin (0.3%), and one drop of 5% povidone-iodine. According to the intravitreal injection protocol recommended in the literature, prior to each injection, the injection site was dried with a sterile cotton-tipped applicator. A wire lid speculum and non-sterile powder-free latex gloves were used for all injection procedures .
(A) Anterior slit lamp optical coherence tomography imaging showing a well-circumscribed nodule. (B) Ultrasound biomicroscopy showing no penetration of the normal sclera (black star).
Color photograph showing the appearance following 5 months topical steroid treatment. The conjunctival nodule has flattened leaving persistent dilated episcleral vessels and increased scleral translucency.
One week post intravitreal injection, the patient had stable corrected visual acuity of 20/200 in the affected right eye. There was localized, inferotemporal hyperemia of the bulbar conjunctiva at the site of the injection. Within the area of hyperemia there was an elevated, subconjunctival erythematous nodule, which was slightly mobile when depressed with a cotton tip applicator (Fig. 1b). There was no evidence of perilimbal vessel injection. On eyelid eversion, there was no tarsal or forniceal conjunctival involvement or foreign body. Anterior exam revealed trace cells and 1+ flare reaction in the anterior chamber. No hypopyon or vitreous cells were noted. Lens, optic nerve and peripheral retinal exam were unremarkable. The left eye was unremarkable and showed no evidence of inflammation.
Slit lamp optical coherence tomography (SL-OCT) (Fig. 2a) and ultrasound biomicroscopy (UBM) (Fig. 2b) revealed a well-circumscribed, solid lesion without scleral penetration. The patient was started on ofloxacin (0.3%) and rimexolone (1%) four times per day in the right eye. Two weeks post-injection, the patient self-discontinued the ofloxacin drops and was using only rimexolone twice daily. While the nodule persisted and conjunctival hyperemia had improved minimally, the patient reported little discomfort. He was transitioned to prednisolone acetate (1%) four times per day and fluorometholone ointment (0.1%) at bedtime. The lesion decreased in size slowly over five months and prednisolone acetate was slowly tapered to one drop daily. The hyperemia resolved and there was trace hyperpigmentation over the area of minimal subconjunctival elevation (Fig. 3). Surgical excision and biopsy was deferred due to improvement with the topical steroid. The patient’s AMD treatment was changed to pro re nata (PRN) optical coherence tomography guided dosing and has not since required or received any further injections. If clinically indicated, another injection site will be considered to prevent further complications.
Safety profiles are closely monitored in the original clinical trials of a medication, but long term use of a medication can subsequently lead to the new presentation of adverse events or drug reactions . The most common ocular adverse events for patients receiving ranibizumab in randomized clinical trials were transient subconjunctival hemorrhage [4-7], intraocular inflammation [1,8-10] and transient and/or sustained elevated intraocular pressure (IOP) [1,4-9]. In one prospective study monitoring for transient post injection IOP elevations after ranibizumab injections, the authors noted that mild injection site reactions such as subconjunctival hemorrhage and /or hyperemia were common (59.2%) .
Transient ischemia of the ocular surface after intravitreal bevacizumab has been reported with nonperfusion of conjunctival, episcleral and scleral vessels around the injection site. This ischemia, hypothesized to be inflammatory in nature, was treated with topical steroids and resolved over three weeks . Our case did not show any signs of nonperfusion; rather, hyperemia of the blood vessels overlying the injection site was seen.
Intravitreal ranibizumab injections have rarely been associated with noninfectious anterior uveitis [1,8-10]. Within one week after injection, our patient developed active anterior inflammation and a localized inflammatory reaction at the site of intravitreal injection. He had previously tolerated multiple bevacizumab and ranibizumab treatments without evidence of post-injection inflammation.
The differential diagnosis at presentation included foreign body reaction, scleral abscess, nodular scleritis, and pyogenic granuloma. Anterior imaging with SL-OCT and UBM revealed a solid nodule that did not involve the sclera, which was consistent with a localized reaction. We believe this reaction occurred as a result of inflammatory materials deposited in the process of injection, creating a pyogenic granuloma reaction and secondary anterior chamber inflammation.
Pyogenic granulomas are red colored tumors that appear on the palpebral or bulbar conjunctiva in areas of vascularized tissue submitted to chronic inflammatory injury [13-19]. Histopathologically, they contain granulation tissue with blood vessels arranged in a fan-shaped configuration and have an associated acute and chronic inflammatory cell infiltrate in a loose connective tissue stroma [15,16]. Although often associated with trauma [14-16], surgery [14-17] and chalazions [13-16], there are reports of pyogenic granuloma formation after foreign bodies such as natural or synthetic fibers , contact lens , scleral buckle , and insect wing . We hypothesize that a component of the intravitreal injection procedure such as talc from a disposable glove, cotton fibers from the sterile applicator, or silicone oil derived from the syringe [20-22] could have triggered foreign body reaction at the level of the conjunctiva. Also, repeated injections in the same quadrant of the eye might have increased the risk of this complication.
Intravitreal anti-VEGF agents including ranibizumab and bevacizumab are a safe and effective treatment for neovascular AMD . Even with the evidence and safety profiles available from the original clinical trials, new presentations of adverse events may occur as the usage of intravitreal anti-VEGF therapy continues to grow. The safety data on these treatment modalities will need to be continuously monitored and the potential risks and benefits of intravitreal anti-VEGF agents should be discussed with patients receiving treatment for neovascular AMD .
CONFLICTS OF INTEREST
Financial support from the LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Institute, and The Macula Foundation Inc. The funding organizations had no role in the design or conduct of this research.
Financial disclosure includes Genentech (Consultant, Research Support-KBF), Alcon (Consultant-KBF) and Alimera (Consultant-KBF).